Collagen Microspheres via Photochemical Crosslinking for Drug Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current microsphere-based drug delivery systems face challenges such as low protein compatibility, instability, and burst release due to the use of synthetic polymers like PLGA, which can damage proteins and result in cytotoxicity from chemical crosslinking agents, while natural extracellular matrix materials like collagen have poor mechanical stability and are difficult to fabricate without compromising biocompatibility.

Innovation Solution

The development of collagen-based microspheres using photochemical crosslinking to control the release of bioactive molecules, employing mild fabrication conditions without organic solvents or vigorous stirring, and using surfactants like TWEEN®20 to stabilize emulsions and enhance mechanical properties.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If chemical crosslinking agents are used to improve mechanical stability of collagen microspheres, then mechanical strength is improved, but cytotoxicity increases due to toxic residual chemicals

Engineering Contradiction:
Improvemechanical stabilityVSAvoidcytotoxicity
Core Design Contradiction:
StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent replaces chemical crosslinking with physical crosslinking methods, specifically photochemical crosslinking using UV irradiation and riboflavin, or thermal crosslinking. This substitution eliminates toxic chemical crosslinking agents while maintaining the mechanical stability of collagen microspheres, resolving the contradiction between strength improvement and cytotoxicity reduction.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the crosslinking mechanism from chemical to physical/photophysical processes. By using UV light irradiation with riboflavin as a photosensitizer, the crosslinking occurs through photochemical reactions that do not leave toxic residues, thus maintaining mechanical stability without introducing cytotoxicity.

Inventive Principle:
Principle #35Parameter changes

2Stability of the object's composition

If vigorous stirring is used during microsphere fabrication to improve mixing, then homogeneity is improved, but mechanical stability deteriorates due to fragmentation of natural extracellular matrix materials

Engineering Contradiction:
ImprovehomogeneityVSAvoidmechanical stability
Core Design Contradiction:
Stability of the object's compositionVSStrength

Solution Approach 1:

The patent applies preliminary crosslinking to the collagen solution before emulsification and microsphere formation. By pre-crosslinking the collagen network, the solution gains mechanical stability that prevents fragmentation during subsequent vigorous stirring and emulsification processes, while still achieving homogeneous distribution of encapsulated molecules.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent employs a dynamic approach where crosslinking density and mechanical properties are adjusted during the fabrication process. The collagen network is crosslinked to appropriate extent before emulsification, providing sufficient mechanical stability during processing while maintaining homogeneity through controlled mixing conditions.

Inventive Principle:
Principle #15Dynamics

3Ease of manufacture

If organic solvents are used in microsphere fabrication to improve processing, then ease of manufacture is improved, but bioactivity deteriorates due to damage to protein drugs

Engineering Contradiction:
Improveprocessing capabilityVSAvoidbioactivity
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent uses water-based or aqueous buffer solutions as the continuous phase during emulsification, creating an inert, non-denaturing environment for protein drugs. This eliminates the need for organic solvents while maintaining processing capability through careful control of emulsification parameters and use of biocompatible surfactants.

Inventive Principle:
Principle #39Inert atmosphere (Inert environment)

Solution Approach 2:

The patent introduces biocompatible surfactants and protective agents as intermediaries during emulsification. These intermediaries enable proper microsphere formation and drug encapsulation without requiring organic solvents, thus maintaining both ease of manufacture and protein bioactivity.

Inventive Principle:
Principle #24Intermediary (Mediator)

4Speed

If rapid release is achieved to improve initial drug availability, then speed is improved, but loss of substance increases due to incomplete release and burst effect

Engineering Contradiction:
Improverelease rateVSAvoiddrug loss
Core Design Contradiction:
SpeedVSLoss of substance

Solution Approach 1:

The patent controls the release profile by adjusting collagen crosslinking density, microsphere porosity, and matrix composition. By optimizing these parameters, the system achieves sustained release with reduced burst effect, improving both release speed control and minimizing drug loss through incomplete release or premature degradation.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method produces microspheres with controlled size and release, maintaining biocompatibility and bioactivity of encapsulated proteins, reducing the initial burst effect, and providing sustained release of bioactive molecules without cytotoxicity, making them suitable for drug delivery and cell culture applications.

Implementation Method 1

providing a solution of collagen monomers or mixture of collagen monomers and other natural extracellular matrix components and initializing the sol-gel transition of the collagen or precipitation of the other natural extracellular matrix components

Methodology Applied
Scientific EffectSol-gel transition: Gel

Implementation Method 2

The microspheres are photochemically crosslinked to control the release of the loaded drugs

Methodology Applied
Scientific EffectPhotochemical crosslinking: Photopolymerisation

Data Source

PatentEP2175978B1Collagen-based microspheres and methods of preparation and use thereof
Publication Date: 2019.02.20 THE UNIVERSITY OF HONG KONG
  • EP2175978B1 patent drawingFigure 1
  • EP2175978B1 patent drawingFigure 2
  • EP2175978B1 patent drawingFigure 3

AI summary

A method of manufacture of ECM microparticles incorporating bioactive molecules for drug delivery has been developed, using a modified emulsification method or a water-in-oil-phase-separation method. The microspheres are photochemically crosslinked to control the release of the bioactive molecules for better drug delivery usage without compromising the biocompatibility of the crosslinked structures. The method uses mild fabrication conditions and simple processes, no toxic chemical crosslinking reagent, which may cause cytotoxicity and calcification after implantation, no organic solvents, which may reduce drug availability and bioactivity, and no vigorous stirring action, which may fragmentize material with poor shape and mechanical stability and thus destabilize the emulsion. The resulting microparticles or microspheres are of controlled size, controlled release, highly biocompatible, and useful for drug delivery as well as cell culture.